Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Triplet Therapy With Bempedoic Acid (ETC 1002) 180 mg, Ezetimibe 10 mg, and Atorvastatin 20 mg in Patients With Elevated LDL C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary) ; Bempedoic acid (Primary) ; Ezetimibe (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Esperion Therapeutics
- 17 Mar 2021 Results evaluating the combination of NEXLETOL (bempedoic acid) 180 mg Tablet, ezetimibe 10 mg and atorvastatin 20 mg in patients with hypercholesterolemia were published in Atherosclerosis as per Esperion Therapeutics Media Release
- 17 Mar 2021 Results published in the Esperion Therapeutics Media Release
- 06 Nov 2017 Status changed from recruiting to completed.